Full-Time

Director of Quality Assurance

Operations

Updated on 8/23/2026

Zevra Therapeutics

Zevra Therapeutics

51-200 employees

Develops rare-disease therapies, including CNS

No salary listed

Boston, MA, USA

Hybrid

The role is remote with approximately 10–15% domestic and international travel.

Bachelor's, Master's

Category
QA & Testing (1)
Required Skills
Quality Assurance (QA)

Get referred to Zevra Therapeutics

See people who can refer or advise you

Requirements
  • 10+ years of progressive experience in the pharmaceutical or biotechnology industry supporting preclinical, clinical, and commercial programs.
  • 7+ years of Quality leadership experience, including vendor oversight, external stakeholder relationship management, and internal quality assurance systems in a virtual environment.
  • 7+ years of experience establishing and administering Good Clinical Practice, Good Laboratory Practice, and Good Distribution Practice compliant systems.
  • A Bachelor's or advanced degree in a scientific or related discipline.
  • Understanding of worldwide Good Practice compliance requirements and quality systems for clinical and commercial products.
  • Leadership experience managing regulatory and health-authority inspections.
  • Ability to travel domestically and internationally as needed, likely approximately 10–15%.
  • Ability to communicate effectively, lead, and influence individuals across multiple functional departments and organizational levels.
  • Strong organizational and time-management skills to balance multiple projects and initiatives.
  • Ability to work with limited direction and oversight.
  • Ability to build and lead highly engaged teams in a changing environment.
  • Excellent written communication and oral presentation skills.
  • In-depth knowledge of Good Practice, 21 CFR, European Union Good Manufacturing Practice, International Council for Harmonisation, International Organization for Standardization, Quality System Regulation, European Union Good Distribution Practice, and other applicable domestic and international regulations, standards, directives, and guidance.
  • Ability to identify and manage contract and vendor resources supporting Quality goals.
  • Experience working in a matrixed virtual organization and building relationships with other functions and contractors or vendors.
  • Experience in a virtual manufacturing environment.
  • Ability to work under pressure, meet deadlines, and contribute to strategic, tactical, and administrative activities.
  • Excellent interpersonal, reading, writing, negotiation, communication, conflict-resolution, public-presentation, organizational, and problem-solving skills.
  • Ability to analyze scientific issues, develop realistic recommendations and plans, and take responsibility for implementation.
Responsibilities
  • Provide technical leadership for administration of the Quality Management System and improve the system and supporting operational processes.
  • Assure that development and commercial operations conducted by the company and its contractors comply with company standards and applicable regulations.
  • Review and approve investigational medicinal product and commercial-product manufacturing documentation, including master batch records and validation protocols and reports.
  • Provide disposition of drug substance, drug product, clinical-trial materials, and commercial finished goods.
  • Ensure, in coordination with Manufacturing, that the serialization system for commercial distribution remains compliant.
  • Administer exception, investigation, corrective and preventive action, and product-complaint management systems for the company, vendors, and operations.
  • Prepare content for and facilitate periodic Quality Management Reviews and support annual product reviews.
  • Engage in day-to-day Quality Vendor Management activities.
  • Conduct or facilitate internal and external vendor audits, self-inspections, and regulatory-inspection readiness activities, including audit planning, execution, reporting, and coordination with contractors.
  • Support periodic Good Practice training and ensure training requirements are met.
  • Prepare, review, approve, and implement standard operating procedures in collaboration with the Head of Quality and other department heads.
  • Lead Quality Review Boards and provide technical expertise for product-quality decisions.
  • Oversee manufacturing investigations with the Manufacturing Team and ensure appropriate corrective and preventive actions are taken.
  • Support continuous-improvement initiatives to optimize quality and compliance.
  • Cross-train and provide backup for Quality Systems as assigned.
  • Build sustainable organizational systems and cross-functional relationships with internal and external stakeholders.
  • Coach and develop cross-functional staff.
Desired Qualifications
  • Experience with new-product launch and implementation of serialization systems and commercial-product complaint processes.
  • Strong customer-service orientation and solution-focused approach.
  • Commitment to the company's mission and core values.
  • Ability to thrive in a fast-paced, innovative remote environment while remaining flexible, proactive, resourceful, hands-on, and efficient.
  • Commitment to collaborative leadership, execution, teamwork, and maintaining a professional culture based on trust and mutual respect.

Zevra Therapeutics develops and commercializes therapies for rare diseases, focusing on CNS disorders with unmet needs. It grows its portfolio through in-house development and strategic acquisitions, including OLPRUVA for urea cycle disorders (acquired via Acer Therapeutics) and azstarys, a once-daily ADHD treatment marketed in the U.S. with Corium. The company is advancing arimoclomol for Niemann-Pick disease type C and engages with the FDA to navigate approvals. Zevra earns revenue from product sales, royalties, and milestone payments from its partnerships, and aims to build a differentiated portfolio that serves underserved patient populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Kissimmee, Florida

Founded

2006

Get referred to Zevra Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $39.7 million, up 53%, with $8.8 million net income.
  • Cash and investments hit $260.2 million on June 30, 2026, funding launches and trials.
  • Real-world arimoclomol data and GeneDx testing broaden NPC diagnosis and prescription conversion.

What critics are saying

  • July 2026 EMA negative opinion on arimoclomol threatens European revenue and credibility.
  • MIPLYFFA drove $30.2 million of Q2 2026 sales; concentration creates existential launch dependence.
  • Celiprolol needs three confirmed events in DiSCOVER; any trial failure wipes pipeline optionality.

What makes Zevra Therapeutics unique

  • MIPLYFFA and OLPRUVA target ultra-rare diseases with FDA and EMA regulatory moats.
  • June 8, 2026 Orange Book listing extends MIPLYFFA patent protection to 2041.
  • Zevra restarted DiSCOVER celiprolol Phase 3 under a 2026 FDA special protocol agreement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

5%

2 year growth

-1%
Yahoo Finance
Aug 7th, 2026
Zevra publishes first real-world NPC data as it seeks EMA re-examination after negative opinion

Zevra Therapeutics published long-term real-world safety and effectiveness data for arimoclomol in adults with Niemann-Pick disease type C. This marks the first extensive evaluation of arimoclomol outside clinical trials. The company is pursuing regulatory options in Europe following a negative opinion from the European Medicines Agency on arimoclomol. Zevra has requested a re-examination of its Marketing Authorization Application. The stock has been volatile, gaining 23.2% over the past week but declining 17.7% over the past month. Year-to-date returns stand at 42.4%, with the stock last closing at $11.88. Latest quarterly results showed net income of $8.75 million on sales of $39.66 million. The European regulatory review adds timing risk and uncertainty for investors.

Yahoo Finance
Aug 6th, 2026
Zevra Therapeutics revenue surges 53% to $39.7M as MIPLYFFA US sales hit $30.2M in Q2 2026

Zevra Therapeutics reported total net revenue of $39.7 million in Q2 2026, marking a 53% increase year-over-year. The company's US sales of MIPLYFFA reached $30.2 million, up 23% sequentially and 40% year-over-year. Operating expenses decreased to $21.0 million, down $3.2 million from the previous year. The company posted net income of $8.8 million, or $0.14 per share. Cash and investments stood at $260.2 million as of 30 June 2026, up $23.4 million from the previous quarter. Since launch, MIPLYFFA has received 184 prescription enrolment forms, with 14 added in Q2. Zevra strengthened its intellectual property position for MIPLYFFA with Orange Book protection through 2041. The company continues advancing its pipeline, including the Phase III DISCOVER trial for celiprolol.

WTOP
Aug 5th, 2026
Zevra Therapeutics: Q2 earnings snapshot.

Zevra Therapeutics: Q2 earnings snapshot. August 5, 2026, 5:18 PM BOSTON (AP) - BOSTON (AP) - Zevra Therapeutics, Inc. (ZVRA) on Wednesday reported second-quarter earnings of $8.8 million. The Boston-based company said it had net income of 14 cents per share. Earnings, adjusted for non-recurring costs, were 25 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 8 cents per share. The specialty pharmaceutical company posted revenue of $39.7 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $32.3 million. Keep Watching Kent Island restaurant adds a million new oysters to Chesapeake Bay Kent Island restaurant adds a million new oysters to Chesapeake Bay This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ZVRA at https://www.zacks.com/ap/ZVRA

MarketBeat
Jul 29th, 2026
Zevra Therapeutics (ZVRA) expected to announce quarterly earnings on Wednesday.

Zevra Therapeutics (ZVRA) expected to announce quarterly earnings on Wednesday. July 29, 2026 Key points. * Zevra Therapeutics is expected to report Q2 2026 results after the market closes on August 5. Analysts forecast earnings of $0.08 per share and revenue of approximately $33.9 million. * In its prior quarter, Zevra exceeded expectations, reporting EPS of $0.18 versus the $0.06 consensus and revenue of $36.22 million versus $31.96 million expected. * The stock recently traded at $9.55, down 1.8%, while analysts maintain a "Moderate Buy" consensus and an average price target of $26.86. * MarketBeat previews the top five stocks to own by August 1st. Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) will likely be issuing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of $0.08 per share and revenue of $33.8830 million for the quarter. Individuals may visit the the company's upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET. Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.12. The firm had revenue of $36.22 million for the quarter, compared to the consensus estimate of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. On average, analysts expect Zevra Therapeutics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year. Zevra Therapeutics trading down 1.8%. Shares of NASDAQ ZVRA traded down $0.18 during mid-day trading on Wednesday, hitting $9.55. The company had a trading volume of 214,486 shares, compared to its average volume of 1,355,924. Zevra Therapeutics has a 1 year low of $7.16 and a 1 year high of $15.03. The company has a market capitalization of $564.66 million, a price-to-earnings ratio of 4.79 and a beta of 0.85. The stock's 50-day moving average price is $12.35 and its 200-day moving average price is $10.50. Wall Street analyst weigh in. Several research analysts have commented on the company. Guggenheim cut their target price on Zevra Therapeutics from $29.00 to $24.00 and set a "buy" rating for the company in a research note on Monday. Weiss Ratings downgraded shares of Zevra Therapeutics from a "buy (b-)" rating to a "hold (c)" rating in a report on Friday, May 22nd. HC Wainwright restated a "buy" rating and issued a $26.00 price objective on shares of Zevra Therapeutics in a research report on Tuesday, June 23rd. Wall Street Zen raised shares of Zevra Therapeutics from a "hold" rating to a "buy" rating in a research note on Sunday, July 12th. Finally, Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a report on Tuesday, June 9th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $26.86. Institutional trading of Zevra Therapeutics. Several institutional investors and hedge funds have recently modified their holdings of ZVRA. Marshall Wace LLP bought a new stake in Zevra Therapeutics in the 3rd quarter valued at $8,676,000. Rubric Capital Management LP increased its holdings in shares of Zevra Therapeutics by 60.8% in the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company's stock worth $17,253,000 after purchasing an additional 740,584 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in shares of Zevra Therapeutics by 15.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company's stock worth $36,720,000 after buying an additional 550,000 shares in the last quarter. Nantahala Capital Management LLC boosted its stake in Zevra Therapeutics by 34.0% during the third quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company's stock valued at $18,753,000 after buying an additional 500,000 shares during the last quarter. Finally, Algert Global LLC purchased a new position in Zevra Therapeutics during the 3rd quarter valued at approximately $3,980,000. 35.03% of the stock is currently owned by institutional investors. About Zevra Therapeutics. Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Zevra Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list. While Zevra Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.

Yahoo Finance
Jul 24th, 2026
Zevra stock plunges 23% after EU rejects arimoclomol marketing application

Zevra Therapeutics shares fell 23% on Friday after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on the company's marketing application for arimoclomol, a treatment for Niemann-Pick disease type C. The committee concluded the drug's effectiveness had not been clearly proven, citing uncertainties in trial data handling and analysis. Zevra plans to request a re-examination and will submit a detailed response. CEO Neil F. McFarlane said the company remains confident in its evidence and is committed to finding pathways for European patients. H.C. Wainwright maintained its Buy rating and $26 price target, calling the setback "a headwind, but not insurmountable." Arimoclomol is already approved in the US as MIPLYFFA, generating $87.4 million in net revenue for the full year 2025.